v ::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::
ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

LUNG EXPOSURE DURING RADIATION THERAPY FOR BREAST CANCER: A SYSTEMATIC REVIEW OF PUBLISHED LUNG DOSES 2019-2020

AUTHORS:

Dr Fahad Ahmad Khan, Dr Urwah Kafeel, Dr Erum Ramzan

ABSTRACT:

Aim: We report a methodical audit of lung radiation portions from bosom malignant growth radiotherapy. Methods: Studies portraying bosom malignant growth radiotherapy regimens distributed during 2019– 2020 and detailing lung portion incorporated. Our current research conducted at Mayo Hospital, Lahore from March 2019 to February 2020. Dosages analyzed between various nations, anatomical areas lighted, methods and utilization of breathing variation. Results: 478 regimes from 34 nations distinguished. The mean normal ipsilateral lung portion (MLDipsi) was 9.0 Gy. The MLDipsi for radiation therapy in the supine position without respiratory adaptation was 9.5 Gy for radiation therapy with whole thoracic/somatic divider (WB/CW), 12.4 Gy when the axillary/supraclavicular fossa was illuminated, and 15.1 Gy with light expansion of the internal mammary chain; respiratory variation decreased MLDipsi by 1 Gy, 2 Gy and 4 Gy separately (p < 0.006). With respect to radiation therapy for VWD and Crohn's disease, DLIPS was lowest for tilted (1.2 Gy) or parallel decubitus digressions (0.8 Gy). The most notable MLDipsi was for IMRT in the supine position (9.4 Gy). Results: The normal mean of the contralateral lung portion (MLDcont) for WB/CW radiotherapy was higher for IMRT (3.0 Gy) than for digressions (0.8 Gy). Conclusion: Portions of lung from radiation therapy for malignant growth of the chest differed considerably around the world, even between examinations with comparable regimens. Lymph node examination and IMRT use an enlarged introduction, while respiratory transformation and location of the inclined/horizontal decubitus decrease it. Keywords: Lung Exposure, Radiation Therapy, Breast Cancer.

FULL TEXT

<
Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.